Funding Rounds
HepaRegeniX

HepaRegeniX July 2024 Series C Funding Round

HepaRegeniX

Small molecule MKK4 inhibitors to treat acute and chronic liver diseases

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series C

Raised Amount: $16.00M

Raised Date: 2024-07-10

Investors